23 results
8-K
EX-1.1
NAMS
NewAmsterdam Pharma Company N.V.
9 Aug 24
Other Events
5:23pm
) to the Company’s knowledge, there are no events or circumstances that would reasonably be expected to form the basis of an order for clean-up
10-Q
2024 Q1
NAMS
NewAmsterdam Pharma Company N.V.
8 May 24
Quarterly report
4:30pm
, research and development efforts, business operations and environmental damage resulting in costly clean-up and liabilities under applicable laws
10-K
2023 FY
NAMS
NewAmsterdam Pharma Company N.V.
28 Feb 24
Annual report
8:00am
in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials
8-K
EX-1.1
NAMS
NewAmsterdam Pharma Company N.V.
15 Feb 24
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
4:18pm
or circumstances that would reasonably be expected to form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any
F-3
EX-1.2
qikef wh4b3tx
7 Dec 23
Shelf registration (foreign)
4:16pm
424B3
7qr96l6 5aydph
15 Aug 23
Prospectus supplement
4:52pm
6-K
EX-99.2
464a41wtei
14 Aug 23
NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer
4:52pm
POS AM
jbfm9qzj676 r49xl
7 Aug 23
Prospectus update (post-effective amendment)
7:56am
6-K
EX-99.2
l2rwoi7x
7 Aug 23
Research and development expenses
7:24am
424B3
nheh3 hgy6
9 Jun 23
Prospectus supplement
9:43pm
6-K
EX-1.1
21lpyrunydh j4j
9 Jun 23
Current report (foreign)
9:39pm
424B3
vwtu9
8 Jun 23
Prospectus supplement
5:01pm
424B3
t1o5d13
6 Jun 23
Prospectus supplement
4:20pm
424B3
emu9i7
25 Apr 23
Prospectus supplement
8:14am
POS AM
ippy0f
17 Apr 23
Prospectus update (post-effective amendment)
9:09am
F-1
vuz k89jn
19 Dec 22
Registration statement (foreign)
6:22pm
424B3
b166o8k39mk8lyxm2f
18 Oct 22
Prospectus supplement
4:41pm
F-4/A
vhw3cn dl
13 Oct 22
Registration of securities (foreign) (amended)
5:18pm